Pancreatic Polypeptide Tumor
16
0
1
11
Key Insights
Highlights
Success Rate
79% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
18.8%
3 terminated out of 16 trials
78.6%
-7.9% vs benchmark
0%
0 trials in Phase 3/4
73%
8 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (16)
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery
Laser Tissue Welding - Distal Pancreatectomy Sealing Study
Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors
Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu